1-4 of 4
Tara L. Lin
Close
Sort by
Journal Articles

Pevonedistat with azacitidine in older patients with TP53 -mutated AML: a phase 2 study with laboratory correlates

Clinical Trials & Observations
Antoine N. Saliba, Scott H. Kaufmann, Eytan M. Stein, Prapti A. Patel, Maria R. Baer, Wendy Stock, Michael Deininger, William Blum, Gary J. Schiller, Rebecca L. Olin, Mark R. Litzow, Tara L. Lin, Brian J. Ball, Michael M. Boyiadzis, Elie Traer, Olatoyosi Odenike, Martha L. Arellano, Alison Walker, Vu H. Duong, Tibor Kovacsovics, Robert H. Collins, Abigail B. Shoben, Nyla A. Heerema, Matthew C. Foster, Kevin L. Peterson, Paula A. Schneider, Molly Martycz, Theophilus J. Gana, Leonard Rosenberg, Sonja Marcus, Ashley O. Yocum, Timothy Chen, Mona Stefanos, Alice S. Mims, Uma Borate, Amy Burd, Brian J. Druker, Ross L. Levine, John C. Byrd, James M. Foran
Journal: Blood Advances
Blood Adv (2023) 7 (11): 2360–2363.
https://doi.org/10.1182/bloodadvances.2022008625
Published: 2023
Includes: Supplemental data
Journal Articles

Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML

Clinical Trials & Observations
Geoffrey L. Uy, Laura F. Newell, Tara L. Lin, Stuart L. Goldberg, Matthew J. Wieduwilt, Robert J. Ryan, Stefan Faderl, Jeffrey E. Lancet
Journal: Blood Advances
Blood Adv (2022) 6 (17): 4989–4993.
https://doi.org/10.1182/bloodadvances.2021006468
Published: 2022
Includes: Supplemental data
Journal Articles

Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome

Clinical Trials & Observations
Aaron T. Gerds, Bart L. Scott, Peter Greenberg, Tara L. Lin, Daniel A. Pollyea, Amit Verma, Monique Dail, Yuning Feng, Cherie Green, Connie Ma, Bruno C. Medeiros, Mark Yan, Kasra Yousefi, William Donnellan
Journal: Blood Advances
Blood Adv (2022) 6 (4): 1152–1161.
https://doi.org/10.1182/bloodadvances.2021005240
Published: 2022
Includes: Supplemental data
Journal Articles

Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses

Clinical Trials & Observations
Tara L. Lin, David A. Rizzieri, Daniel H. Ryan, Gary J. Schiller, Jonathan E. Kolitz, Geoffrey L. Uy, Donna E. Hogge, Scott R. Solomon, Matthew J. Wieduwilt, Robert J. Ryan, Stefan Faderl, Jorge E. Cortes, Jeffrey E. Lancet
Journal: Blood Advances
Blood Adv (2021) 5 (6): 1719–1728.
https://doi.org/10.1182/bloodadvances.2020003510
Published: 2021
Includes: Supplemental data